2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2021
Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis
Ellingson MK, Oliveira CR, Sheth SS, Sullivan EL, Torres A, Shapiro ED, Niccolai LM. Patterns of recommended vaccine receipt among women ages 24–45 years: a cross-sectional analysis. BMC Public Health 2021, 21: 1283. PMID: 34193100, PMCID: PMC8247221, DOI: 10.1186/s12889-021-11340-4.Peer-Reviewed Original ResearchConceptsMid-adult womenVaccine receiptCross-sectional analysisHPV vaccineOngoing case-control studyReceipt of influenzaHealth care visitsCase-control studyWomen ages 24Quarter of adultsLogistic regression analysisCare visitsIndividual vaccinesHealthcare utilizationMultiple vaccinesVaccineAge 24White womenWomenDemographic characteristicsRegression analysisLower ratesInfluenzaReceiptPast year